How many stocks does RA CAPITAL MANAGEMENT, L.P. own?

As of Q1 2026, RA CAPITAL MANAGEMENT, L.P. holds 85 positions in their 13F portfolio.

What is RA CAPITAL MANAGEMENT, L.P.'s largest holding?

ASND at 24.9% of portfolio, worth $2.4B.

What is RA CAPITAL MANAGEMENT, L.P.'s total portfolio value?

$9.4B as of Q1 2026, tracked across 85 holdings.

Is RA CAPITAL MANAGEMENT, L.P. a hedge fund?

RA CAPITAL MANAGEMENT, L.P. is an institutional investment manager required to file SEC 13F reports. This includes hedge funds, mutual funds, pension funds, and other institutions managing over $100M.

How often does RA CAPITAL MANAGEMENT, L.P. report?

13F filings are due quarterly, approximately 45 days after each quarter end.

How has RA CAPITAL MANAGEMENT, L.P.'s portfolio changed in Q1 2026?

View RA CAPITAL MANAGEMENT, L.P.'s latest portfolio changes, new positions, and exits for Q1 2026 on HoldingsIntel.

What is RA CAPITAL MANAGEMENT, L.P.'s investment strategy?

RA CAPITAL MANAGEMENT, L.P. is classified as a Balanced Allocator fund based on HoldingsIntel's Fund DNA analysis of 6 behavioral dimensions.

HoldingsIntel

RA CAPITAL MANAGEMENT, L.P. Holdings Q1 2026 - Portfolio & Conviction Scores | HoldingsIntel

RA CAPITAL MANAGEMENT, L.P.

Institutional investor · Portfolio as of Q1 2026

SEC EDGAR SourceSEC Filings

$9.4B

AUM

Positions

Q1 2026

Filing

Rating · 2.0

Quarterly Portfolio Change

Activity profile

$ moved · Q1'26

New27%Increased22%Decreased0%Exited50%

Composition

Equity vs derivatives

Equity100%Puts0%Calls0%

Holding period

Avg 2.4 years

<1Q16%1-4Q21%1-2Y15%2Y+47%

Q1 2026 Summary

Active quarter - 24 new positions, 10 exits, 17 increased. Top move: DNTH (INCREASED, conviction 76). Portfolio: $9.4B across 85 positions.

Portfolio Allocation

Top holdings by portfolio weight

ASND24.92%

PCVX7.07%

RYTM6.14%

TYRA4.95%

SION4.21%

EWTX3.48%

NAMS3.24%

NUVL2.75%

DNTH2.32%

MLYS2.21%

Other2.20%

Position Outcomes

Best and worst performing positions by estimated return

Top Winners

SION5Q held

SIONNA THERAPEUTICS INC

Avg $11.56 · $283.9M est. P&L

Est. P&L

+247.92%

ASND30Q held

ASCENDIS PHARMA A/S

Avg $95.48 · $1.5B est. P&L

Est. P&L

+151.89%

NAMS14Q held

NEWAMSTERDAM PHARMA COMPANY

Avg $14.11 · $203.7M est. P&L

Est. P&L

+151.21%

Top Losers

Upgrade to Pro to see the worst-performing positions.

View plans

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Top Holdings85 positions

Export CSV(Pro)

Activity:

Stock	Shares	Value	Weight	Price Trend	Avg Buy	Est. P&L	Held	Conviction
ASND ADR ASCENDIS PHARMA A/S	10.3M	$2.4B	24.9%	—	$95.48	+151.89%	30 qtrssince 2018-Q4	Unchanged 0
PCVX VAXCYTE INC	11.5M	$666.8M	7.1%	—	$49.77	+5.26%	24 qtrssince 2020-Q2	Increased 66
RYTM RHYTHM PHARMACEUTICALS INC	6.7M	$579.8M	6.1%	—	$38.85	+132.98%	30 qtrssince 2018-Q4	Unchanged 0
TYRA TYRA BIOSCIENCES INC	12.2M	$467.2M	5.0%	—	$15.72	+135.58%	19 qtrssince 2021-Q3	Unchanged 0
SION SIONNA THERAPEUTICS INC	9.9M	$397.1M	4.2%	—	$11.56	+247.92%	5 qtrssince 2025-Q1	Unchanged 0
EWTX EDGEWISE THERAPEUTICS INC	10.4M	$328.5M	3.5%	—	$17.63	+87.68%	9 qtrssince 2024-Q1	Unchanged 0
NAMS NEWAMSTERDAM PHARMA COMPANY	9.6M	$305.7M	3.2%	—	$14.11	+151.21%	14 qtrssince 2022-Q4	Unchanged 0
NUVL NUVALENT INC	2.5M	$259.6M	2.8%	—	$92.70	+10.36%	3 qtrssince 2025-Q3	Increased 68
DNTH DIANTHUS THERAPEUTICS INC	2.6M	$219.2M	2.3%	—	$37.57	+129.36%	9 qtrssince 2024-Q1	Increased 76
MLYS MINERALYS THERAPEUTICS INC	7.7M	$208.4M	2.2%	—	$19.13	+43.13%	13 qtrssince 2023-Q1	Increased 55
Showing 10 of 85 results.75 more with Pro.PROUpgrade to see all →